Drug Profile
Research programme: uroguanylin-based nanotherapeutics - Pfizer/Synergy Pharmaceuticals
Latest Information Update: 16 Oct 2023
Price :
$50
*
At a glance
- Originator BIND Therapeutics; Synergy Pharmaceuticals Inc
- Developer Pfizer; Synergy Pharmaceuticals Inc
- Class Antineoplastics
- Mechanism of Action Enterotoxin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastrointestinal cancer
Most Recent Events
- 16 Oct 2023 Discontinued - Preclinical for Gastrointestinal cancer in USA (unspecified route) (Pfizer pipeline, August 2023)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Gastrointestinal-cancer in USA
- 15 Mar 2016 Preclinical trials in Gastrointestinal cancer in USA (unspecified route) before March 2016